Does Paxlovid Improve Covid-19 Outcomes in the Omicron Era?

For higher-risk people, yes.

Nirmatrelvir and ritonavir, marketed as Paxlovid by Pfizer, are antiviral drugs that inhibit a protease vital to the viral replication of SARS-CoV-2. Paxlovid was FDA-approved based on the EPIC-HR trial, conducted during the Delta variant’s dominance. Patients taking nirmatrelvir-ritonavir had a significantly lower risk of progression to severe Covid-19…